Tyra Biosciences, Inc. (TYRA) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 4, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TYRA SEC filings page.
This page shows Tyra Biosciences, Inc. (TYRA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
TYRA is a development-stage cash consumer: rising R&D drives losses while minimal capital spending keeps cash use primarily operating-driven.
The earnings-to-cash gap in FY2025 is meaningful: net loss was-$119.9M , versus operating cash flow of-$95.1M , indicating that accounting expenses included noncash items and/or timing effects. With capital expenditures of only$141K , free cash flow of-$95.3M shows that cash consumption is R&D-led rather than equipment-led.
R&D increased from
FY2025 liabilities of
Financial Health Signals
Tyra Biosciences, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Tyra Biosciences, Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Tyra Biosciences, Inc. reported a net loss of $119.9M while operations used $95.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Tyra Biosciences, Inc.'s EBITDA was -$48.9M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 56.1% from the same quarter a year earlier. Against the prior quarter it is down 16.7%.
Tyra Biosciences, Inc. reported -$45.6M in net income in Q2 2026. This represents a decrease of 62.1% from the same quarter a year earlier. Against the prior quarter it is down 15.9%.
Tyra Biosciences, Inc. earned -$0.69 per diluted share (EPS) in Q2 2026. This represents a decrease of 46.8% from the same quarter a year earlier. Against the prior quarter it is down 7.8%.
Not reported for Q2 2026.
Cash & Balance Sheet
Tyra Biosciences, Inc. recorded an outflow of $31.1M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 31.3% from the same quarter a year earlier. Against the prior quarter it is up 4.6%.
Tyra Biosciences, Inc. held $73.8M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Tyra Biosciences, Inc.'s ROE was -12.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 3.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.7 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Tyra Biosciences, Inc. invested $39.2M in research and development in Q2 2026. This represents an increase of 61.2% from the same quarter a year earlier. Against the prior quarter it is up 17.1%.
Tyra Biosciences, Inc. invested $66K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 112.9% from the same quarter a year earlier. Against the prior quarter it is down 25.0%.
Not reported for Q2 2026.
TYRA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $39.2M+61.2% | $33.5M+34.1% | N/A | $25.5M+12.2% | $24.3M+35.1% | $25.0M+45.1% | N/A | $22.7M+17.8% |
| SG&A Expenses | $9.8M+37.3% | $8.5M+23.8% | N/A | $7.5M+26.5% | $7.1M+29.1% | $6.9M+34.5% | N/A | $5.9M |
| Operating Income | -$49.0M-55.8% | -$42.0M-31.9% | N/A | -$32.9M-15.2% | -$31.5M-33.7% | -$31.9M-42.7% | N/A | -$28.6M-19.4% |
| EBITDA | -$48.9M-56.1% | -$41.9M-32.0% | N/A | -$32.8M-15.1% | -$31.3M-33.6% | -$31.7M-42.8% | N/A | -$28.5M-19.4% |
| Net Income | -$45.6M-62.1% | -$39.3M-39.6% | N/A | -$29.9M-24.4% | -$28.1M-50.2% | -$28.1M-54.7% | N/A | -$24.0M-13.5% |
| EPS (Basic) | -$0.69-46.8% | -$0.64-36.2% | -$0.56-30.2% | -$0.50-22.0% | -$0.47-46.9% | -$0.47-34.3% | -$0.43+18.9% | -$0.41+16.3% |
| EPS (Diluted) | -$0.69-46.8% | -$0.64-36.2% | -$0.56-30.2% | -$0.50-22.0% | -$0.47-46.9% | -$0.47-34.3% | -$0.43+18.9% | -$0.41+16.3% |
| Diluted Shares (Avg) | 66M+10.8% | 62M+4.1% | N/A | 60M+1.4% | 60M+1.5% | 59M+13.6% | N/A | 59M+37.3% |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
TYRA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $383.4M+19.2% | $412.0M+20.0% | $282.6M-22.3% | $301.9M-20.7% | $321.5M-18.1% | $343.5M-15.1% | $363.6M+61.0% | $380.6M+59.7% |
| Current Assets | $367.0M+21.4% | $394.6M+21.6% | $265.4M-23.6% | $281.2M-23.1% | $302.2M-20.2% | $324.6M-16.9% | $347.5M+64.2% | $365.6M+62.8% |
| Cash & Equivalents | $73.8M-25.0% | $85.0M-15.7% | $77.4M-15.9% | $62.0M-40.4% | $98.5M-1.0% | $100.7M-60.4% | $92.0M+58.5% | $103.9M-51.8% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $29.7M+53.5% | $24.5M+22.7% | $23.4M+14.8% | $21.3M+16.6% | $19.4M+17.9% | $19.9M+34.2% | $20.4M-5.5% | $18.3M+13.1% |
| Current Liabilities | $24.6M+78.8% | $19.3M+35.2% | $18.1M+24.0% | $15.9M+28.3% | $13.8M+32.6% | $14.2M+63.4% | $14.6M-4.8% | $12.4M+21.9% |
| Non-Current Liabilities | $5.1M-9.0% | $5.2M-8.5% | $5.3M-8.2% | $5.5M-7.9% | $5.6M-7.5% | $5.7M-7.3% | $5.8M-7.2% | $5.9M-1.8% |
| Total Equity | $353.7M+17.1% | $387.6M+19.8% | $259.2M-24.5% | $280.5M-22.6% | $302.1M-19.7% | $323.5M-17.0% | $343.2M+68.0% | $362.3M+63.1% |
| Retained Earnings | -$456.1M-48.3% | -$410.6M-46.9% | -$371.3M-47.7% | -$337.4M-49.5% | -$307.6M-52.5% | -$279.5M-52.7% | -$251.3M-52.5% | -$225.7M-59.0% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
TYRA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$31.1M-31.2% | -$32.6M-27.9% | -$23.6M-20.6% | -$22.4M-25.0% | -$23.7M-130.8% | -$25.5M-15.6% | -$19.6M-44.8% | -$17.9M-4.4% |
| Depreciation & Amortization | $138K-1.4% | $138K-3.5% | $132K-8.3% | $131K+31.0% | $140K+40.0% | $143K+17.2% | $144K+41.2% | $100K0.0% |
| Stock-Based Compensation | $10.2M+60.4% | $7.8M+22.2% | N/A | $7.6M+0.1% | $6.4M+44.6% | $6.4M+56.1% | N/A | $7.6M+73.0% |
| Capital Expenditures | $66K+112.9% | $88K+528.6% | $57K+850.0% | $39K-25.0% | $31K-93.4% | $14K-89.7% | $6K-99.0% | $52K-37.3% |
| Free Cash Flow | -$31.1M-31.3% | -$32.7M-28.2% | -$23.7M-20.8% | -$22.4M-24.9% | -$23.7M-121.0% | -$25.5M-14.9% | -$19.6M-38.6% | -$17.9M-4.2% |
| Investing Cash Flow | $17.9M-14.4% | -$120.2M-475.5% | $34.4M+394.1% | -$14.8M-168.7% | $20.9M+114.4% | $32.0M+77.2% | $7.0M+104.8% | $21.6M+26072.3% |
| Financing Cash Flow | $2.1M+260.5% | $160.4M+7233.5% | $4.7M+563.3% | $647K-12.9% | $583K+56.3% | $2.2M-98.9% | $706K+117.9% | $743K+59.1% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TYRA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -12.9%-3.6pp | -10.1%-1.4pp | N/A | -10.7%-4.0pp | -9.3%-4.3pp | -8.7%-4.0pp | N/A | -6.6%+2.9pp |
| Return on Assets | -11.9%-3.1pp | -9.5%-1.3pp | N/A | -9.9%-3.6pp | -8.7%-4.0pp | -8.2%-3.7pp | N/A | -6.3%+2.6pp |
| Current Ratio | 14.91-7.0x | 20.49-2.3x | 14.67-9.1x | 17.71-11.8x | 21.94-14.5x | 22.78-22.1x | 23.81+10.0x | 29.55+7.4x |
| Debt-to-Equity | 0.080.0x | 0.060.0x | 0.090.0x | 0.080.0x | 0.060.0x | 0.060.0x | 0.060.0x | 0.050.0x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Tyra Biosciences, Inc. TYRA | FY2025 | N/A | -$119.9M | N/A | $1.5B | — |
| Bicara Therapeutics BCAX | FY2025 | N/A | -$137.9M | N/A | $1.6B | — |
| Rigel Pharmaceuticals Inc RIGL | FY2025 | $294.3M | $367.0M | N/A | $923.2M | 62/100 |
| Anaptysbio Inc ANAB | FY2025 | $234.6M | -$13.2M | -5.6% | $1.7B | 79/100 |
| Palvella Therapeutics Inc PVLA | FY2025 | N/A | -$41.7M | N/A | $2.2B | — |
| Septerna, Inc. SEPN | FY2025 | $46.0M | -$48.9M | N/A | $1.8B | 47/100 |
Where Tyra Biosciences, Inc. Ranks
Frequently Asked Questions
Is Tyra Biosciences, Inc. profitable?
No, Tyra Biosciences, Inc. (TYRA) reported a net income of -$119.9M in fiscal year 2025.
What is Tyra Biosciences, Inc.'s EBITDA?
Tyra Biosciences, Inc. (TYRA) had EBITDA of -$132.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Tyra Biosciences, Inc.'s return on equity (ROE)?
Tyra Biosciences, Inc. (TYRA) has a return on equity of -46.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Tyra Biosciences, Inc.'s free cash flow?
Tyra Biosciences, Inc. (TYRA) recorded an outflow of $95.3M in free cash flow during fiscal year 2025. This represents a -35.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Tyra Biosciences, Inc.'s operating cash flow?
Tyra Biosciences, Inc. (TYRA) recorded an outflow of $95.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Tyra Biosciences, Inc.'s total assets?
Tyra Biosciences, Inc. (TYRA) had $282.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Tyra Biosciences, Inc.'s capital expenditures?
Tyra Biosciences, Inc. (TYRA) invested $141K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Tyra Biosciences, Inc. spend on research and development?
Tyra Biosciences, Inc. (TYRA) invested $102.9M in research and development during fiscal year 2025.
What is Tyra Biosciences, Inc.'s current ratio?
Tyra Biosciences, Inc. (TYRA) had a current ratio of 14.67 as of fiscal year 2025, which is generally considered healthy.
What is Tyra Biosciences, Inc.'s debt-to-equity ratio?
Tyra Biosciences, Inc. (TYRA) had a debt-to-equity ratio of 0.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Tyra Biosciences, Inc.'s return on assets (ROA)?
Tyra Biosciences, Inc. (TYRA) had a return on assets of -42.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Tyra Biosciences, Inc.'s P/E ratio?
Tyra Biosciences, Inc. (TYRA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $1.5B as of Sep 4, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Tyra Biosciences, Inc.'s price-to-sales ratio?
Tyra Biosciences, Inc. (TYRA) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $1.5B as of Sep 4, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Tyra Biosciences, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Tyra Biosciences, Inc. (TYRA) held $77.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $95.1M over that year. Dividing the one by the other, the reported balance equals about 10 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Tyra Biosciences, Inc.'s Piotroski F-Score?
Tyra Biosciences, Inc. (TYRA) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Tyra Biosciences, Inc.'s earnings high quality?
Tyra Biosciences, Inc. (TYRA) reported a net loss of $119.9M while operations used $95.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.